Abstract:Objective To investigate the clinical value of serum metabonomic profile of pancreatic cancer using nuclear magnetic resonance (NMR)-based metabonomics.Methods The retrospective case-control study was adopted.The clinical data of 23 patients with pancreatic cancer (PC group) and 16 healthy volunteers (control group) who were admitted to the Fujian Medical University Union Hospital between December 2013 and December 2014 were collected.The serum of the 2 groups was measured by 1H NMR spectroscopy.Multivariate statistical analyses were performed to identify the characteristic metabolites in the 2 groups,including principal component analysis (PCA),partial least squares discriminant analysis (PLS-DA) and orthogonal partial least squares discriminant analysis (OPLS-DA).Observation indicators included:(1) multivariate statistical analysis of serum metabonomic profile,results of PCA,PLS-DA and OPLS-DA,(2) screening of metabolites.Measurement data with normal distribution were presented as x ± s.The comparison between groups was evaluated with the t test.The count data were analyzed using the chi-square test.Results (1) The multivariate statistical analysis of serum metabonomic profile:results of PCA showed that expression rates of principal component 1 (PC1) and principal component 2 (PC2) to original data were 54.9％ and 23.5％,with both cumulative contribution rate of 78.4％.Results of PLS-DA showed that the separative trend between PC group and control group was appeared,and variance of X and Y matrixes and predictive value were 0.254,0.816 and 0.385.Results of OPLS-DA showed that the differences of samples between the 2 groups were further increased,and differential metabolites were screened according to the distinction of scores between the 2 groups,value of R2X,R2Y and Q2 was 0.254,0.816 and 0.433.(2) Screening of metabolites:35 serum metabolites were detected in the 2 groups.Compared with the control group,levels of 3-hydroxybuyarate,citrate,formate,glutamate,isoleucine,methionine and phenylalanine in the PC group were elevated (r =0.524,0.511,0.656,0.566,0.503,0.498,0.648,P ＜0.05),and levels of 3-methylhistidine,alanine,glutamine,LDL and VLDL in the PC group were decreased (r =-0.607,-0.508,-0.560,-0.568,-0.559,P ＜ 0.05).Conclusions Compared with healthy controls,several amino acids,citrate and lipoproteins demonstrate the metabolic differences in the serum of patients with pancreatic cancer.NMR based metabonomic profile technology can distinguish the difference of serum metabolites between patients with pancreatic cancer and healthy controls.NMR based metabonomic technology may be a promising method for the diagnosis of pancreatic cancer.

Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results

Metabolite Detection of Pancreatic Carcinoma by in Vivo Proton MR Spectroscopy at 3T: Initial Results Rilevazione Dei Metaboliti Del Carcinoma Pancreatico Mediante L'utilizzo in Vivo Della Spettroscopia Protonica a Risonanza Magnetica a 3T: Risultati Preliminari

Chemical Exchange Saturation Transfer for Pancreatic Ductal Adenocarcinoma Evaluation

Metabolic Alterations in Pancreatic Cancer Detected by In Vivo 1H-MR Spectroscopy: Correlation with Normal Pancreas, PET Metabolic Activity, Clinical Stages, and Survival Outcome

Proton Nuclear Magnetic Resonance Spectroscopy-Based Metabonomic Research on Pancreatic Cancer Tissue

Initial Application of in vivo Proton MR Spectroscopy on Hepatic Neoplasm on 3.0T

Metabolomic Profiling of Serum from Human Pancreatic Cancer Patients Using 1H NMR Spectroscopy and Principal Component Analysis

Discrimination of Metabolic Profiles of Pancreatic Cancer from Chronic Pancreatitis by High‐resolution Magic Angle Spinning 1H Nuclear Magnetic Resonance and Principal Components Analysis

Distinguishing Pancreatic Cancer from Chronic Pancreatitis and Healthy Individuals by 1H Nuclear Magnetic Resonance-Based Metabonomic Profiles

Preliminary Study of Proton MR Spectroscopy in Distinguishing Benign from Malignant Intracranial Lesions and Predicting the Malignancy of Tumors

Quantification of choline compounds in human hepatic tumors by proton MR spectroscopy at 3 T

Pathologic characterization of human prostate tissue with proton MR spectroscopy.

31P MR Spectroscopy in the Pancreas: Repeatability, Comparison With Liver, and Pilot Pancreatic Cancer Data

Analysis of Nuclear Magnetic Resonance-Based Metabonomics of Pancreatic Cancer

Quantitative in vivo proton MR spectroscopic assessment of lipid metabolism: Value for breast cancer diagnosis and prognosis

Understanding metabolomic characteristics of pancreatic ductal adenocarcinoma by HR-MAS NMR detection of pancreatic tissues

Metabolic analysis using HR‐MAS in prostate tissue for prostate cancer diagnosis

Quantitative Analysis of Prostate Adenocarcinoma by Magnetic Resonance Spectroscopy:Correlation Study with Systemic Biopsy

Metabonomic Characteristics of Human Lung Cancer Using High Resolution 1H NMR Spectroscopy and Multivariate Data Analysis

Study of Metabonomic Profiles of Human Esophageal Carcinoma by Use of High-Resolution Magic-Angle Spinning 1H NMR Spectroscopy and Multivariate Data Analysis

Metabonomic Studies of Human Hepatocellular Carcinoma Using High-Resolution Magic-Angle Spinning 1H NMR Spectroscopy in Conjunction with Multivariate Data Analysis.